文献速递免疫规划传染病防控与疫情报告

中国广西肠道病毒A71型疫苗在重症手足口病病例中的有效性

Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China.
PubMed 文献 · Vaccine · 2019-12-28

采用检测阴性设计病例对照研究,纳入2017年1月1日至2018年12月31日广西12岁以下重症手足口病病例2779例,其中EV-A71阳性838例、阴性对照1941例;EV-A71感染与死亡风险升高相关(aOR 8.8,95%CI 1.3-61.6),调整后疫苗有效性单剂为81.4%、两剂为88.3%。

要点

  • 检测阴性设计显示重症手足口病中EV-A71阳性838例、阴性对照1941例。
  • EV-A71感染与死亡风险升高相关,aOR为8.8(95%CI 1.3-61.6)。
  • 调整后疫苗有效性单剂81.4%、两剂88.3%,灭活疫苗在真实世界中表现良好。

核心结论

  • 广西重症手足口病病例中EV-A71阳性率下降,6-36月龄儿童接种疫苗后EV-A71感染风险降低。
  • 灭活疫苗在真实世界重症手足口病病例中表现良好。

研究设计与样本

  • 检测阴性设计病例对照研究,纳入2017年1月1日至2018年12月31日广西12岁以下重症手足口病病例。
  • 共纳入2779例重症手足口病病例,EV-A71核酸阳性838例为病例组,EV-A71核酸阴性1941例为对照组。
  • 疫苗有效性采用logistic回归估计。

主要发现

  • EV-A71阳性病例中6-36月龄比例低于EV-A71阴性对照。
  • EV-A71感染与死亡风险升高相关,aOR为8.8(95%CI 1.3-61.6)。
  • 调整后疫苗有效性单剂为81.4%,两剂为88.3%。

临床怎么用

  • 原文结论提示6-36月龄儿童使用疫苗可降低EV-A71感染风险。
  • 原文结论提示灭活疫苗在真实世界重症手足口病病例中表现良好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hand, foot, and mouth disease (HFMD) caused by enterovirus A71 (EV-A71) is a major public health issue in China that poses severe risks to children's health, especially those under the age of 3. Since 2016, EV71 vaccines developed by three Chinese manufacturers have been approved for use, and clinical trials of these vaccines have demonstrated protection against EV-A71 infection. However, few studies have assessed the effectiveness of these vaccines in real-world settings. METHODS: A test-negative design case-control study was used to estimate vaccine effectiveness (VE) in cases of severe HFMD. We obtained information including EV-A71 vaccination status from the Local Center for Disease Control and Prevention (CDC) on all severe HFMD cases under 12 years in age in Guangxi, China, from Jan. 1, 2017, to Dec. 31, 2018. Enterovirus infection was laboratory confirmed by local CDCs. Individuals with a positive EV-A71 nucleic acid test result were assigned to the case group, and those with negative EV-A71 nucleic acid test results were assigned to the control group. We estimated VE using logistic regression. RESULTS: A total of 2779 severe HFMD cases were enrolled in the study; 838 children were EV-A71 positive cases, and 1941 children were EV-A71 negative controls. The proportion of EV-A71 positive cases aged 6-36 months was lower than that for EV-A71 negative controls. EV-A71 infection was associated with an increased risk of mortality (aOR, 8.8; 95% CI, 1.3-61.6). The adjusted VE was 81.4% and 88.3% for one dose and two doses, respectively. CONCLUSION: Our findings suggest that the rate of EV-A71 has fallen among severe HFMD cases in Guangxi and that the risk for EV-A71 infection in 6-36-month-old children has been reduced by use of the vaccine. Inactivated vaccines performed well in severe HFMD cases in a real-world setting.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jiang L, Wang J, Zhang C, et al. Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China. Vaccine. 2019. PMID: 31892446. doi:10.1016/j.vaccine.2019.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。